Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.

Inclusion Criteria: Healthy Subjects: * Subjects must have a calculated glomerular filtration rate (GFR) by Cockcroft-Gault Equation ≥80 mL/min. Severe Renal Impaired Patients: * Patients not on dialysis with severe renal failure with a creatinine clearance \< 30 mL/min as determined by Cockcroft-Gault Equation. * Renal function should have been stable within the 3 months prior to study start. * Patients with diabetes and/or hypertension who are in otherwise in good health may be included. However patients with diabetes must not have clinical evidence of gastropathy or enteropathy. Exclusion Criteria: All Subjects/Patients: * History of multiple and recurring allergies or allergy to the investigational compound/compound class being used in this study * History of retinal macular edema. * History of any significant cardiovascular events such as myocardia infarction, valvular disease, angina, ischemic heart disease, dilated cardiomyopathy, dysrhythmia. * History of immunocompromise, including a positive HIV (ELISA and Western blot) test result. Severe Renal Impaired Patients: * Use of any highly potent CYP3A4 inhibitor (e.g. erythromycin, ketoconazole, itraconazole) within 2 weeks prior to dosing. * Use of beta blocker therapy within two (2) weeks prior to dosing. Other protocol-defined inclusion/exclusion criteria may apply